CClinicalTrials.gg
CompletedNCT04986956WCCEUpdated Jan 30, 2024

Whole Coffee Cherry Study

An interventional study of Whole coffee cherry extract and Placebo in Effect of Drug, sponsored by Auburn University. Completed at 1 site in United States. Open to participants aged 40 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Auburn University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
323
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
All
01

Study summary

There has been increasing interest in natural dietary supplements that may support healthy cognition. Recent studies have demonstrated promising effects of bioactive phytochemicals (e.g., polyphenols) on cardiovascular and endocrine health outcomes. As such, an increasingly intriguing line of inquiry is whether materials high in these compounds may also have effects on psychological measures. Preliminary evidence suggests that polyphenols may improve cognition, for example, particularly in aging populations. Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (\<2%; \<4mg) levels of caffeine. WCCE has been previously associated with increased serum concentrations of both circulating and exosomal brain derived neurotrophic factor (BDNF), in addition to increased alertness and decreased fatigue. However, few well-powered and well-designed studies have been conducted despite the mounting preliminary evidence. Here, the investigators propose a study to examine the long-term effects of a 200mg dose of WCCE on measures of cognition.

Read the detailed description

The investigators will conduct a virtual study whereby participants will be given either 200mg WCCE or placebo to take every day for 28 days. Every 7 days, participants will take a cognitive assessment via the internet using a platform called Millisecond (https://www.millisecond.com/). The cognitive assessment will be composed of tasks that broadly test working memory, focus, and attention. Compliance checks will be administered daily via the participant's smartphone. This study will be conducted in a double-blind fashion, such that the experimental team and the participants are unaware of group assignment (200mg vs. placebo). Blinding information will be held by the study sponsor, VDF FutureCeuticals, Inc. Group assignment will be determined by random number generator, with restrictions to ensure equal group sizes, and equal distribution of males/females in each group. Participants, between 40-65 years of age, with no known psychiatric or neurological conditions, will be recruited from the general community via online advertisements, social media posts, community flyers, and newspaper ads (if needed). Participants will be excluded if they are taking medications known to alter cognitive functioning (psychotropic medications such as fluoxetine, benzodiazepines, etc. or other medications such as insulin). The primary variables of interest will be the behavioral performance on the cognitive tasks over time, inclusive of reaction time and accuracy. Compensation will be commensurate with study participation, with a maximum payout of $125.

02

Conditions studied

  • Effect of Drug

Keywords

  • coffee cherry
  • cognition
  • virtual study
  • internet
03

In context

Lead sponsor

Auburn University is the lead sponsor of 72 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Between 40-65 years of age
  • No diagnosed psychiatric or neurological condition
  • Reliable internet service
  • Moderate computer literacy
  • Individuals must have a smartphone
  • Individuals must have a laptop, desktop, or iPad

Exclusion criteria

Exclusion Criteria:

  • Individuals taking medications known to alter cognitive functioning (e.g., psychotropic medications such as fluoxetine, benzodiazepines, etc.)
  • Individuals taking medications that alter metabolic function, such as insulin or metformin.
  • Shift workers
  • Health conditions that would prevent an individual from successfully completing the study (I.e., motor control conditions such as Parkinson's, or psychiatric conditions such as ADHD)
  • Individuals with metabolic conditions
  • Have had or currently have cancer
  • Have taken CBD or multivitamins in the last 2 weeks
  • Individuals with unreliable or no internet access/service
  • Individuals who are unable to use a smartphone or are lacking the computer literacy necessary to complete the study remotely
  • Individuals without a laptop, desktop or iPad that would prevent them from completing the study.
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
323 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    The placebo will be a simple microcellulose, which is generally-recognized-as-safe (GRAS) and commonly used in food products.

    Dietary Supplement: Placebo

  • Active comparator
    Whole coffee cherry extract

    Whole coffee cherry extract (WCCE; otherwise known as the generally-recognized-as-safe (GRAS) supplement Neurofactor(TM)), is a proprietary, safe, powdered extract of whole coffee cherries from coffea arabica with high levels of polyphenols and substantially low (\<2%; \<4mg) levels of caffeine. The only content of the supplement is WCCE - there are no excipients, binders, or flow agents, nor are there any other materials. The coffee cherry is subjected to a food-grade water ethanol extraction; thus, after extraction, only 100% coffee-based components remain. 200mg of WCCE will be administered daily for 28 days.

    Dietary Supplement: Whole coffee cherry extract

Interventions

  • Dietary supplementWhole coffee cherry extract

    200mg WCCE

    Also known as: WCCE, CCE

  • Dietary supplementPlacebo

    Placebo for comparison to WCCE

06

What researchers measure

Primary outcomes

  1. Behavioral Measures - Change in Go/NoGo Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  2. Behavioral Measures - Change in N-back Reaction Time

    Response/reaction/accuracy time for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  3. Behavioral Measures - Change in Face-Name Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  4. Behavioral Measures - Change in Stroop Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  5. Behavioral Measures - Change in Flanker Task Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  6. Behavioral Measures - Change in Symbol Search Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  7. Behavioral Measures - Change in Trail Making Reaction Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

  8. Behavioral Measures - Change in Face in the Crowd Time

    Response/reaction time/accuracy for each stimuli will be recorded in ms using Inquisit. Reaction times will be calculated for correct and incorrect trials separately.

    Time frame: Collected at baseline (pre- and post-consumption) and then once weekly (pre-consumption) through the duration of the study (approximately 28 days)

Secondary outcomes

  1. Daily Self-reported Sleep

    The investigators will assess changes in the amount of sleep a participant had on a daily basis for the entire duration of the study via a single daily question asking about the number of hours of sleep the participant had the night before.

    Time frame: The question will be administered daily for the duration of the study (approximately 28 days)

  2. Weekly Self-reported Sleep Hygiene

    The investigators will assess changes in sleep via an in-house questionnaire (administered every 7 days for the entire length of the study) that inquires about the quality of sleep for the past 7 days, as well as how the participant would rate their sleep for the night prior to the assessment. These questions are scored as 1 = excellent, 2 = good, 3 = average, 4 = poor, and 5 = terrible.

    Time frame: Questions are administered weekly for the duration of the study (approximately 28 days)

  3. Weekly Self-reported Mood

    The investigators will assess changes in mood every 7 days for the duration of the study. This questionnaire, developed in-house, asks about how often the participant has felt alert, focused, attentive, in-control, sleepy, determined, motivated, happy, and upset the participant has felt in the last 7 days. The scale is scored as 1 = always, 2 = most of the time, 3 = about half of the time, 4 = sometimes, and 5 = never.

    Time frame: The questionnaire is administered weekly for the duration of the study (approximately 28 days)

  4. Daily Self-reported Mood

    The investigators will assess changes in mood via a daily question about how good/bad the participant feels on a scale of 0-100 (0 being worst they have ever felt, and 100 being the best they have ever felt).

    Time frame: The question will be administered daily for the duration of the study (approximately 28 days)

Other outcomes

  1. Compliance

    The investigators will assess compliance via daily questionnaires delivered to the participant's smartphone.

    Time frame: Daily for the duration of the study (approximately 28 days)

07

Study locations

1 site
  • Auburn University
    Auburn, Alabama 36849, United States
08

References and documents

Publications

  • Cao H, Ou J, Chen L, Zhang Y, Szkudelski T, Delmas D, Daglia M, Xiao J. Dietary polyphenols and type 2 diabetes: Human Study and Clinical Trial. Crit Rev Food Sci Nutr. 2019;59(20):3371-3379. doi: 10.1080/10408398.2018.1492900. Epub 2018 Nov 19. PubMed 29993262 ↗
  • Hurtado-Barroso S, Quifer-Rada P, Rinaldi de Alvarenga JF, Perez-Fernandez S, Tresserra-Rimbau A, Lamuela-Raventos RM. Changing to a Low-Polyphenol Diet Alters Vascular Biomarkers in Healthy Men after Only Two Weeks. Nutrients. 2018 Nov 14;10(11):1766. doi: 10.3390/nu10111766. PubMed 30441880 ↗
  • Mendonca RD, Carvalho NC, Martin-Moreno JM, Pimenta AM, Lopes ACS, Gea A, Martinez-Gonzalez MA, Bes-Rastrollo M. Total polyphenol intake, polyphenol subtypes and incidence of cardiovascular disease: The SUN cohort study. Nutr Metab Cardiovasc Dis. 2019 Jan;29(1):69-78. doi: 10.1016/j.numecd.2018.09.012. Epub 2018 Oct 4. PubMed 30459074 ↗
  • Schuster J, Mitchell ES. More than just caffeine: psychopharmacology of methylxanthine interactions with plant-derived phytochemicals. Prog Neuropsychopharmacol Biol Psychiatry. 2019 Mar 8;89:263-274. doi: 10.1016/j.pnpbp.2018.09.005. Epub 2018 Sep 10. PubMed 30213684 ↗
  • Sarubbo F, Moranta D, Pani G. Dietary polyphenols and neurogenesis: Molecular interactions and implication for brain ageing and cognition. Neurosci Biobehav Rev. 2018 Jul;90:456-470. doi: 10.1016/j.neubiorev.2018.05.011. Epub 2018 May 23. PubMed 29753753 ↗
  • Shukitt-Hale B, Miller MG, Chu YF, Lyle BJ, Joseph JA. Coffee, but not caffeine, has positive effects on cognition and psychomotor behavior in aging. Age (Dordr). 2013 Dec;35(6):2183-92. doi: 10.1007/s11357-012-9509-4. Epub 2013 Jan 24. PubMed 23344884 ↗
  • Whyte AR, Cheng N, Fromentin E, Williams CM. A Randomized, Double-Blinded, Placebo-Controlled Study to Compare the Safety and Efficacy of Low Dose Enhanced Wild Blueberry Powder and Wild Blueberry Extract (ThinkBlue) in Maintenance of Episodic and Working Memory in Older Adults. Nutrients. 2018 May 23;10(6):660. doi: 10.3390/nu10060660. PubMed 29882843 ↗
  • Robinson JL, Hunter JM, Reyes-Izquierdo T, Argumedo R, Brizuela-Bastien J, Keller R, Pietrzkowski ZJ. Cognitive short- and long-term effects of coffee cherry extract in older adults with mild cognitive decline. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2020 Nov;27(6):918-934. doi: 10.1080/13825585.2019.1702622. Epub 2019 Dec 12. PubMed 31829793 ↗
  • Robinson JL, Yanes JA, Reid MA, Murphy JE, Busler JN, Mumford PW, Young KC, Pietrzkowski ZJ, Nemzer BV, Hunter JM, Beck DT. Neurophysiological Effects of Whole Coffee Cherry Extract in Older Adults with Subjective Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Pilot Study. Antioxidants (Basel). 2021 Jan 20;10(2):144. doi: 10.3390/antiox10020144. PubMed 33498314 ↗
  • Heimbach JT, Marone PA, Hunter JM, Nemzer BV, Stanley SM, Kennepohl E. Safety studies on products from whole coffee fruit. Food Chem Toxicol. 2010 Aug-Sep;48(8-9):2517-25. doi: 10.1016/j.fct.2010.06.025. Epub 2010 Jun 18. PubMed 20600539 ↗
  • Yashin A, Yashin Y, Wang JY, Nemzer B. Antioxidant and Antiradical Activity of Coffee. Antioxidants (Basel). 2013 Oct 15;2(4):230-45. doi: 10.3390/antiox2040230. PubMed 26784461 ↗
  • Reed, R.A., et al., Acute Low and Moderate Doses of a Caffeine-Free Polyphenol-Rich Coffeeberry Extract Improve Feelings of Alertness and Fatigue Resulting from the Performance of Fatiguing Cognitive Tasks. Journal of Cognitive Enhancement, 2018.
  • Reyes-Izquierdo T, Nemzer B, Shu C, Huynh L, Argumedo R, Keller R, Pietrzkowski Z. Modulatory effect of coffee fruit extract on plasma levels of brain-derived neurotrophic factor in healthy subjects. Br J Nutr. 2013 Aug 28;110(3):420-5. doi: 10.1017/S0007114512005338. Epub 2013 Jan 14. PubMed 23312069 ↗
  • Abdel-Aziz K, Larner AJ. Six-item cognitive impairment test (6CIT): pragmatic diagnostic accuracy study for dementia and MCI. Int Psychogeriatr. 2015 Jun;27(6):991-7. doi: 10.1017/S1041610214002932. Epub 2015 Jan 29. PubMed 25630996 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04986956
Lead sponsor
Auburn University
Collaborators
VDF FutureCeuticals Inc.
Responsible party
Jennifer L. Robinson, Ph.D. (Professor, Auburn University) — Principal investigator
First posted
Aug 3, 2021
Start date
Feb 1, 2022
Primary completion
Oct 31, 2022
Completion
Jan 29, 2024
Last update
Jan 30, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion